Renal tolerance of fleroxacin in healthy volunteers.
In order to evaluate kidney tolerance of fleroxacin, a new fluoroquinolone, we performed a volunteer study with 16 healthy males, 20-27 years old. On three consecutive days 800 mg of fleroxacin was administered orally. Alanine-aminopeptidase and distal- and pan-tubular antigens were determined in 24 h urine collections with specific monoclonal antibodies. Routine haematological and biochemical parameters were determined daily and were in the normal range during the follow-up. No significant changes in excretion of alanine-aminopeptidase and of the urinary antigens were observed during the three days of fleroxacin administration and on the following three days. The results obtained in this volunteer study indicate that fleroxacin has no nephrotoxic side effects.
Mondorf
A W
AW
Abteilung für Nephrologie, Klinikum der J. W. Goethe Universität, Frankfurt/Main, Federal Republic of Germany.
Buch
A
A
Steinbacher
G
G
Rüdel
C
C
Falkenberg
F W
FW
D000328:Adult; D000626:Aminopeptidases / Q000652:urine; D000890:Anti-Infective Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal; D000941:Antigens / Q000652:urine; D018826:CD13 Antigens; D002939:Ciprofloxacin / Q000009:adverse effects / Q000031:analogs & derivatives*; D003404:Creatinine / Q000097:blood; D016576:Fleroxacin; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008297:Male
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D000941:Antigens; D002939:Ciprofloxacin; D003404:Creatinine; D000626:Aminopeptidases; D018826:CD13 Antigens; D016576:Fleroxacin